Intrinsic value of Genesis Healthcare - GEN

Previous Close

$1.64

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$1.64

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of GEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  5,481
  5,607
  5,751
  5,913
  6,092
  6,289
  6,503
  6,735
  6,985
  7,253
  7,540
  7,846
  8,172
  8,518
  8,885
  9,275
  9,687
  10,123
  10,583
  11,070
  11,583
  12,124
  12,694
  13,295
  13,928
  14,595
  15,296
  16,034
  16,811
  17,627
Variable operating expenses, $m
  5,294
  5,416
  5,554
  5,710
  5,882
  6,071
  6,277
  6,500
  6,741
  6,998
  7,251
  7,546
  7,859
  8,192
  8,545
  8,920
  9,316
  9,736
  10,178
  10,646
  11,140
  11,660
  12,209
  12,787
  13,395
  14,036
  14,711
  15,421
  16,168
  16,953
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  5,294
  5,416
  5,554
  5,710
  5,882
  6,071
  6,277
  6,500
  6,741
  6,998
  7,251
  7,546
  7,859
  8,192
  8,545
  8,920
  9,316
  9,736
  10,178
  10,646
  11,140
  11,660
  12,209
  12,787
  13,395
  14,036
  14,711
  15,421
  16,168
  16,953
Operating income, $m
  187
  192
  197
  203
  210
  218
  226
  235
  244
  255
  288
  300
  313
  326
  340
  355
  371
  387
  405
  423
  443
  464
  486
  509
  533
  558
  585
  613
  643
  674
EBITDA, $m
  457
  467
  479
  492
  507
  524
  542
  561
  582
  604
  628
  653
  681
  709
  740
  772
  807
  843
  881
  922
  965
  1,010
  1,057
  1,107
  1,160
  1,216
  1,274
  1,335
  1,400
  1,468
Interest expense (income), $m
  446
  499
  353
  363
  374
  387
  401
  417
  434
  452
  472
  493
  516
  540
  566
  594
  623
  654
  687
  721
  758
  796
  837
  880
  925
  973
  1,023
  1,076
  1,132
  1,191
  1,252
Earnings before tax, $m
  -312
  -161
  -165
  -171
  -177
  -183
  -191
  -199
  -208
  -217
  -205
  -216
  -228
  -240
  -254
  -268
  -283
  -299
  -316
  -334
  -353
  -373
  -394
  -417
  -440
  -465
  -491
  -519
  -547
  -578
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -312
  -161
  -165
  -171
  -177
  -183
  -191
  -199
  -208
  -217
  -205
  -216
  -228
  -240
  -254
  -268
  -283
  -299
  -316
  -334
  -353
  -373
  -394
  -417
  -440
  -465
  -491
  -519
  -547
  -578

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,885
  4,998
  5,126
  5,270
  5,430
  5,605
  5,796
  6,003
  6,225
  6,464
  6,720
  6,993
  7,283
  7,592
  7,919
  8,266
  8,634
  9,022
  9,433
  9,866
  10,323
  10,806
  11,314
  11,850
  12,414
  13,008
  13,633
  14,291
  14,983
  15,711
Adjusted assets (=assets-cash), $m
  4,885
  4,998
  5,126
  5,270
  5,430
  5,605
  5,796
  6,003
  6,225
  6,464
  6,720
  6,993
  7,283
  7,592
  7,919
  8,266
  8,634
  9,022
  9,433
  9,866
  10,323
  10,806
  11,314
  11,850
  12,414
  13,008
  13,633
  14,291
  14,983
  15,711
Revenue / Adjusted assets
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
Average production assets, $m
  3,875
  3,964
  4,066
  4,181
  4,307
  4,446
  4,598
  4,762
  4,938
  5,128
  5,331
  5,547
  5,777
  6,022
  6,282
  6,557
  6,849
  7,157
  7,482
  7,826
  8,189
  8,572
  8,975
  9,400
  9,847
  10,318
  10,814
  11,336
  11,885
  12,463
Working capital, $m
  -22
  -22
  -23
  -24
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -40
  -42
  -44
  -46
  -48
  -51
  -53
  -56
  -58
  -61
  -64
  -67
  -71
Total debt, $m
  3,561
  3,662
  3,778
  3,908
  4,051
  4,209
  4,381
  4,567
  4,767
  4,982
  5,212
  5,458
  5,719
  5,997
  6,292
  6,604
  6,935
  7,284
  7,654
  8,044
  8,455
  8,889
  9,347
  9,829
  10,337
  10,871
  11,434
  12,026
  12,649
  13,304
Total liabilities, $m
  4,397
  4,498
  4,613
  4,743
  4,887
  5,045
  5,217
  5,403
  5,603
  5,818
  6,048
  6,293
  6,555
  6,833
  7,127
  7,440
  7,770
  8,120
  8,489
  8,879
  9,291
  9,725
  10,183
  10,665
  11,172
  11,707
  12,269
  12,862
  13,484
  14,140
Total equity, $m
  489
  500
  513
  527
  543
  561
  580
  600
  623
  646
  672
  699
  728
  759
  792
  827
  863
  902
  943
  987
  1,032
  1,081
  1,131
  1,185
  1,241
  1,301
  1,363
  1,429
  1,498
  1,571
Total liabilities and equity, $m
  4,886
  4,998
  5,126
  5,270
  5,430
  5,606
  5,797
  6,003
  6,226
  6,464
  6,720
  6,992
  7,283
  7,592
  7,919
  8,267
  8,633
  9,022
  9,432
  9,866
  10,323
  10,806
  11,314
  11,850
  12,413
  13,008
  13,632
  14,291
  14,982
  15,711
Debt-to-equity ratio
  7.290
  7.330
  7.370
  7.410
  7.460
  7.510
  7.560
  7.610
  7.660
  7.710
  7.760
  7.810
  7.850
  7.900
  7.940
  7.990
  8.030
  8.070
  8.110
  8.150
  8.190
  8.230
  8.260
  8.290
  8.330
  8.360
  8.390
  8.420
  8.440
  8.470
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -312
  -161
  -165
  -171
  -177
  -183
  -191
  -199
  -208
  -217
  -205
  -216
  -228
  -240
  -254
  -268
  -283
  -299
  -316
  -334
  -353
  -373
  -394
  -417
  -440
  -465
  -491
  -519
  -547
  -578
Depreciation, amort., depletion, $m
  270
  275
  282
  289
  297
  306
  316
  326
  337
  349
  340
  353
  368
  384
  400
  418
  436
  456
  477
  498
  522
  546
  572
  599
  627
  657
  689
  722
  757
  794
Funds from operations, $m
  -42
  114
  116
  118
  121
  123
  125
  127
  130
  132
  135
  137
  140
  143
  146
  150
  153
  157
  160
  164
  168
  173
  177
  182
  187
  192
  198
  203
  210
  216
Change in working capital, $m
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
Cash from operations, $m
  -42
  115
  117
  119
  121
  123
  126
  128
  131
  133
  136
  139
  142
  145
  148
  151
  155
  158
  162
  166
  170
  175
  179
  184
  189
  195
  200
  206
  213
  219
Maintenance CAPEX, $m
  -242
  -247
  -253
  -259
  -266
  -274
  -283
  -293
  -303
  -315
  -327
  -340
  -353
  -368
  -384
  -400
  -418
  -436
  -456
  -477
  -498
  -522
  -546
  -572
  -599
  -627
  -657
  -689
  -722
  -757
New CAPEX, $m
  -74
  -89
  -102
  -114
  -127
  -139
  -151
  -164
  -177
  -190
  -203
  -216
  -230
  -245
  -260
  -275
  -291
  -308
  -326
  -344
  -363
  -383
  -403
  -425
  -447
  -471
  -496
  -522
  -549
  -577
Cash from investing activities, $m
  -316
  -336
  -355
  -373
  -393
  -413
  -434
  -457
  -480
  -505
  -530
  -556
  -583
  -613
  -644
  -675
  -709
  -744
  -782
  -821
  -861
  -905
  -949
  -997
  -1,046
  -1,098
  -1,153
  -1,211
  -1,271
  -1,334
Free cash flow, $m
  -358
  -221
  -237
  -254
  -272
  -290
  -309
  -329
  -349
  -371
  -394
  -417
  -442
  -468
  -496
  -524
  -554
  -586
  -619
  -654
  -691
  -729
  -770
  -812
  -857
  -904
  -953
  -1,004
  -1,058
  -1,115
Issuance/(repayment) of debt, $m
  -1,475
  101
  116
  130
  144
  158
  172
  186
  200
  215
  230
  245
  261
  278
  295
  312
  331
  350
  369
  390
  412
  434
  458
  482
  508
  535
  563
  592
  623
  655
Issuance/(repurchase) of shares, $m
  1,885
  172
  178
  185
  193
  201
  210
  220
  230
  241
  230
  243
  257
  271
  287
  303
  320
  338
  357
  378
  399
  422
  445
  470
  497
  524
  554
  584
  617
  651
Cash from financing (excl. dividends), $m  
  410
  273
  294
  315
  337
  359
  382
  406
  430
  456
  460
  488
  518
  549
  582
  615
  651
  688
  726
  768
  811
  856
  903
  952
  1,005
  1,059
  1,117
  1,176
  1,240
  1,306
Total cash flow (excl. dividends), $m
  51
  52
  56
  61
  65
  69
  73
  77
  81
  85
  67
  71
  76
  81
  86
  91
  96
  102
  107
  113
  120
  126
  133
  140
  148
  155
  164
  172
  181
  191
Retained Cash Flow (-), $m
  -1,885
  -172
  -178
  -185
  -193
  -201
  -210
  -220
  -230
  -241
  -230
  -243
  -257
  -271
  -287
  -303
  -320
  -338
  -357
  -378
  -399
  -422
  -445
  -470
  -497
  -524
  -554
  -584
  -617
  -651
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -1,834
  -120
  -122
  -124
  -128
  -132
  -137
  -143
  -149
  -156
  -163
  -172
  -181
  -190
  -201
  -212
  -224
  -236
  -250
  -264
  -279
  -295
  -312
  -330
  -349
  -369
  -390
  -412
  -436
  -460
Discount rate, %
  15.50
  16.28
  17.09
  17.94
  18.84
  19.78
  20.77
  21.81
  22.90
  24.05
  25.25
  26.51
  27.84
  29.23
  30.69
  32.22
  33.83
  35.53
  37.30
  39.17
  41.13
  43.18
  45.34
  47.61
  49.99
  52.49
  55.11
  57.87
  60.76
  63.80
PV of cash for distribution, $m
  -1,588
  -89
  -76
  -64
  -54
  -45
  -37
  -29
  -23
  -18
  -14
  -10
  -7
  -5
  -4
  -2
  -2
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  50.0
  37.0
  27.3
  20.0
  14.7
  10.7
  7.8
  5.6
  4.1
  2.9
  2.2
  1.6
  1.2
  0.8
  0.6
  0.4
  0.3
  0.2
  0.2
  0.1
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Genesis Healthcare, Inc. is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services. As of December 31, 2016, the Company offered inpatient services through its network of 499 skilled nursing and assisted/senior living facilities across 34 states, consisting of 473 skilled nursing facilities and 26 stand-alone assisted/senior living facilities. Its services focus primarily on the medical and physical issues facing elderly patients and are provided by its skilled nursing companies, assisted or senior living communities, integrated and third-party rehabilitation therapy business, and other ancillary services.

FINANCIAL RATIOS  of  Genesis Healthcare (GEN)

Valuation Ratios
P/E Ratio -4
Price to Sales 0
Price to Book -0.5
Price to Tangible Book
Price to Cash Flow 3.7
Price to Free Cash Flow -1.9
Growth Rates
Sales Growth Rate 2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -20.6%
Cap. Spend. - 3 Yr. Gr. Rate 17.4%
Financial Strength
Quick Ratio 2
Current Ratio 0.1
LT Debt to Equity -1022.9%
Total Debt to Equity -1028.6%
Interest Coverage 1
Management Effectiveness
Return On Assets 5.5%
Ret/ On Assets - 3 Yr. Avg. 3.6%
Return On Total Capital -1.4%
Ret/ On T. Cap. - 3 Yr. Avg. -7.4%
Return On Equity 13.8%
Return On Equity - 3 Yr. Avg. 82.5%
Asset Turnover 1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 9.8%
EBITDA Margin - 3 Yr. Avg. 7%
Operating Margin 6.7%
Oper. Margin - 3 Yr. Avg. 4.2%
Pre-Tax Margin -2.4%
Pre-Tax Margin - 3 Yr. Avg. -4.9%
Net Profit Margin -1.1%
Net Profit Margin - 3 Yr. Avg. -4.7%
Effective Tax Rate 13.2%
Eff/ Tax Rate - 3 Yr. Avg. -6.6%
Payout Ratio 0%

GEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the GEN stock intrinsic value calculation we used $5373.74 million for the last fiscal year's total revenue generated by Genesis Healthcare. The default revenue input number comes from 0001 income statement of Genesis Healthcare. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our GEN stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 15.5%, whose default value for GEN is calculated based on our internal credit rating of Genesis Healthcare, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Genesis Healthcare.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of GEN stock the variable cost ratio is equal to 96.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for GEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.9% for Genesis Healthcare.

Corporate tax rate of 27% is the nominal tax rate for Genesis Healthcare. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the GEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for GEN are equal to 70.7%.

Life of production assets of 15.7 years is the average useful life of capital assets used in Genesis Healthcare operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for GEN is equal to -0.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-1084.227 million for Genesis Healthcare - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 101.091 million for Genesis Healthcare is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Genesis Healthcare at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
ENSG Ensign Group 45.01 13.49  str.sell
NHC National Healt 79.77 26.55  str.sell
DVCR Diversicare He 4.95 4.30  sell
ACHC Acadia Healthc 37.49 66.19  str.buy
FVE Five Star Seni 0.440 0.72  sell
CSU Capital Senior 7.91 0.65  str.sell

COMPANY NEWS

▶ Genesis Healthcare: 3Q Earnings Snapshot   [06:17PM  Associated Press]
▶ [$$] Sears Owner Eddie Lampert Is Unrepentant   [Oct-18-18 11:12AM  The Wall Street Journal]
▶ Genesis Healthcare Inc Class A to Host Earnings Call   [Aug-08-18 06:30AM  ACCESSWIRE]
▶ Genesis Healthcare: 2Q Earnings Snapshot   [05:56PM  Associated Press]
▶ Home DNA Testing Gains Popularity in Aging Japan   [Jul-17-18 05:00PM  Bloomberg]
▶ The 5 Best Healthcare Stocks of 2018 (So Far)   [Jul-09-18 09:06AM  Motley Fool]
▶ Genesis Healthcare: 1Q Earnings Snapshot   [May-10-18 06:13AM  Associated Press]
▶ Interim Report First Quarter 2018   [May-08-18 11:04AM  GlobeNewswire]
▶ $30M deal: Genesis to sell 51% stake in China subsidiary   [Apr-24-18 08:25AM  American City Business Journals]
▶ Genesis selling off 2 dozen skilled nursing facilities in Texas   [Apr-12-18 10:38AM  American City Business Journals]
▶ Passing of Genmab A/S Annual General Meeting   [09:43AM  GlobeNewswire]
▶ Genesis Healthcare reports 4Q loss   [06:27AM  Associated Press]
▶ At $1.17, Is Genesis Healthcare Inc (NYSE:GEN) A Buy?   [Mar-02-18 05:31PM  Simply Wall St.]
▶ [$$] Genesis Healthcare Refinances Debt Load Amid Restructuring   [Feb-23-18 05:06PM  The Wall Street Journal]
▶ Genesis Healthcare gets some debt relief   [12:45PM  American City Business Journals]
▶ Nursing home giant Genesis eyes approval for $26M Dracut facility   [Feb-08-18 04:45PM  American City Business Journals]
▶ Genesis Healthcare reports 3Q loss   [05:01AM  Associated Press]
▶ Companies Paying Americans the Least   [Oct-27-17 04:22PM  24/7 Wall St.]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.